期刊文献+

间充质干细胞外泌体在脓毒症治疗中的应用研究进展 被引量:3

Advances in exosomes derived from the mesenchymal stem cells in the treatment of sepsis
原文传递
导出
摘要 间充质干细胞(MSC)外泌体是MSC在静息或活化状态下释放到细胞外基质中的膜性小囊泡,直径为30~150nm。最近的研究表明,MSC外泌体可作为重要的信号传导介质,有效转运mRNA、微小RNA和蛋白质等生物活性物质至靶细胞,在调控组织再生修复及免疫调节方面发挥重要作用。本文对MSC外泌体的生物学特性、作用机制及在脓毒症治疗中作用的研究进展作一综述,以期为临床治疗脓毒症提供依据。 Exosomes derived from mesenchymal stem cells (MSCs) are small membrane vesicles with diameters in 30-150 nm, which are secreted into extracellular matrix by MSCs in resting or activated state. Recent studies have found that exosomes secreted by MSCs can be used as important signal transduction mediator, which can transport bioactive substances such as mRNA, microRNA, and proteins effectively to target cells, and play important roles in regulating tissue regeneration and immunomodulation. Here we give an overview of biological properties, mechanisms, and the roles in treating sepsis of exosome derived from MSCs, in order to provide some basises to highlight the MSCs-exosomes therapy in sepsis.
作者 王珊 尹海燕 Wang Shan;Yin Haiyan(Department of Intensive Care Unit, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China)
出处 《中华烧伤杂志》 CAS CSCD 北大核心 2019年第1期77-80,共4页 Chinese Journal of Burns
基金 广东省自然科学基金(2015A030313735) 广东省科技计划(2014A020212651).
关键词 间充质干细胞 外泌体 脓毒症 微小RNA Mesenchymal stem cells Exosomes Sepsis MicroRNA
作者简介 通信作者:尹海燕,Email:yinhaiyan1867@126.com.
  • 相关文献

参考文献4

二级参考文献47

  • 1Hotchkiss RS,Karl IE.The pathophysiology and treatment of sepsis[J].N Engl J Med,2003,348 (2):138-150.
  • 2Calvano SE,Xiao W,Richards DR,et al.A network-based analysis of systemic inflammation in humans[J].Nature,2005,437 (7061):1032-1037.
  • 3Bone RC.Sir Isaac Newton,sepsis,SIRS,and CARS[J].Crit Care Med,1996,24 (7):1125-1128.
  • 4Marshall JC.Such stuff as dreams are made on:mediator-directed therapy in sepsis[J].Nat Rev Drug Discov,2003,2 (5):391-405.
  • 5Opal SM,Laterre PF,Francois B,et al.Effect of eritoran,an antagonist of MD2-TLR4,on mortality in patients with severe sepsis:the ACCESS randomized trial[J].JAMA,2013,309 (11):1154-1162.
  • 6Osuchowski MF,Welch K,Yang H,et al.Chronic sepsis mortality characterized by an individualized inflammatory response[J].Immunol,2007,179 (1):623-630.
  • 7Ertel W,Kremer JP,Kenney J,et al.Down-regulation of proinflammatory cytokine release in whole blood from septic patients[J].Blood,1995,85 (5):1341-1347.
  • 8Sinistro A,Almerighi C,Ciaprini C,et al.Downregulation of CD40 ligand response in monocytes from sepsis patients[J].Clin Vaccine Immunol,2008,15 (12):1851-1858.
  • 9Favalli EG,Desiati F,Atzeni F,et al.Serious infections during antiTNFalpha treatment in rheumatoid arthritis patients[J].Autoimmun Rev,2009,8 (3):266-273.
  • 10Boomer JS,To K,Chang KC,et al.Immunosuppression in patients who die of sepsis and multiple organ failure[J].JAMA,2011,306(23):2594-2605.

共引文献38

同被引文献23

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部